MedTrace Logo

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

NCT05714371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 618

Last updated 2023-02-06

No results posted yet for this study

Summary

This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy \[IO\], or targeted therapy \[TT\] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence or end of continuous eligibility or end of the study period.

Conditions

Interventions

DRUG

Nivolumab

Patients receiving nivolumab

DRUG

Ipilimumab + nivolumab

Patients receiving ipilimumab + nivolumab

DRUG

Pembrolizumab

Patients receiving pembrolizumab

DRUG

Dabrafenib + trametinib

Dabrafenib + trametinib

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-02
Primary Completion
2022-01-27
Completion
2022-01-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05714371 on ClinicalTrials.gov